Systemic Lupus Erythematosus Treatment Guidelines

Foundation Therapy for All Patients

Hydroxychloroquine is recommended for all SLE patients unless contraindicated, as it reduces disease activity, prevents flares, and improves survival 1
The dose of hydroxychloroquine must not exceed 5 mg/kg of real body weight to minimize retinal toxicity risk 1
Ophthalmological screening is mandatory at baseline, after 5 years, then yearly thereafter 1
Photoprotection with sunscreens prevents cutaneous flares 1
Low-dose aspirin should be given to patients with antiphospholipid antibodies, those receiving corticosteroids, or those with cardiovascular risk factors 1
Calcium and vitamin D supplementation is required for all patients on long-term glucocorticoids 1

For acute flares, intravenous methylprednisolone pulses provide immediate therapeutic effect and enable lower starting doses of oral steroids 1, 3
Initial oral prednisone dosing ranges from 0.5-1 mg/kg/day depending on severity, followed by aggressive tapering 3
Chronic maintenance glucocorticoid therapy must be minimized to less than 7.5 mg/day and withdrawn when possible to prevent organ damage 1, 2

Methotrexate is recommended for skin and joint manifestations 1
Azathioprine is recommended for maintenance therapy, particularly suitable for women contemplating pregnancy 1, 2
Mycophenolate mofetil is recommended for renal and non-renal manifestations except neuropsychiatric disease 1, 2
Cyclophosphamide is recommended for severe organ-threatening disease, especially renal, cardiopulmonary, or neuropsychiatric manifestations 1

For inflammatory/immune-mediated mechanisms: high-dose intravenous methylprednisolone plus cyclophosphamide 1
For thrombotic/embolic mechanisms: anticoagulation with warfarin 1

For significant thrombocytopenia: initial pulse IV methylprednisolone followed by moderate/high-dose glucocorticoids combined with immunosuppressive agents 1, 2

Belimumab is FDA-approved for active extrarenal SLE in patients receiving standard therapy, and for active lupus nephritis 1
Anifrolumab is FDA-approved for moderate-to-severe extrarenal SLE 1
Voclosporin is FDA-approved for lupus nephritis 1
Rituximab may be considered for refractory cases, particularly hematological manifestations 1, 3

Use validated activity indices at each visit 1, 3
Monitor anti-dsDNA, C3, C4, complete blood count, creatinine, proteinuria, and urine sediment regularly 1, 3
SLE patients have 5-fold increased mortality risk; screen aggressively for infections, cardiovascular disease, hypertension, diabetes, dyslipidemia, osteoporosis, avascular necrosis, and malignancies 4, 1

Safe medications during pregnancy: prednisolone, azathioprine, hydroxychloroquine, and low-dose aspirin 1, 2
Contraindicated medications: mycophenolate mofetil, cyclophosphamide, and methotrexate 1

NSAIDs should only be used judiciously for limited periods in patients at low risk for complications 4
Failure to perform kidney biopsy before treating lupus nephritis leads to suboptimal therapy selection 1, 2